Stephen Charles

Chief Executive Officer

Currently, Steve serves as the CEO and co–founder of SATOR Therapeutics, an early stage company with an oncolytic virus platform. Prior to this, as an Executive in Residence at BioEnterprise, he served as CEO for Lobesity, an early stage company with a novel treatment for obesity; the CTO for Diasome Pharmaceuticals, a clinical stage company with a liver targeting technology for the treatment of diabetes; and the CTO for Aphesin LifeSciences, an early stage company with a novel opioid detox platform. Prior to BioEnterprise, Steve founded Kodiak Sciences (Nasdaq: KOD), a biopharmaceutical company developing first/best–in–class treatments for retinal diseases, and played key development roles in multiple successful, marketed product platforms, including J&J Ortho’s Vitros central laboratory immunodiagnostic system, GE Healthcare’s Biacore biosensor, CooperVision’s Proclear range of contact lenses, Medtronic’s Endeavor drug–eluting coronary stent, and several PEGylated biopharmaceuticals.